Evidence map›Paper›PMID 42420928›Full record

ArticleBMC public health2026

Socioeconomic determinants of COVID-19 vaccination and mortality: a cross-national path analysis.

Fulya Ipek-Erdem, Esra Erpek, Volkan Genç, Aybars Bars, Sabri Erdem, Servet Akar

Abstract read
In one paragraph

Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fulya Ipek-ErdemFaculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Amasya University, Amasya, Turkey. fulya.erdem@amasya.edu.tr.ORCID http://orcid.org/0000-0001-7606-042X
Esra ErpekDepartment of Internal Medicine, Division of Rheumatology, İzmir Katip Çelebi University, Atatürk Education and Research Hospital, İzmir, Turkey.ORCID http://orcid.org/0000-0003-3540-4905
Volkan GençDokuz Eylül University, Social Sciences Institute, İzmir, Turkey.ORCID http://orcid.org/0000-0003-2184-482X
Aybars BarsDokuz Eylül University, Social Sciences Institute, İzmir, Turkey.ORCID http://orcid.org/0000-0002-8051-9165
Sabri ErdemFaculty of Business, Department of Business Administration, Dokuz Eylül University, İzmir, Turkey.ORCID http://orcid.org/0000-0001-6766-3202
Servet AkarDepartment of Internal Medicine, Division of Rheumatology, İzmir Katip Çelebi University, Atatürk Education and Research Hospital, İzmir, Turkey.ORCID http://orcid.org/0000-0002-3734-1242

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNumerous clinical and epidemiological studies demonstrated that COVID-19 vaccines and boosters reduce infection and mortality; however, the extent to which these effects vary across socioeconomic and political contexts remains insufficiently explained at the population level. Cross-national evidence remains fragmented, with many studies examining vaccination coverage and macro-structural determinants separately rather than evaluating how structural readiness, vaccination and booster coverage interact simultaneously to influence mortality outcomes, particularly during the post-Omicron phase. Consequently, it remains unclear how structural development and policy capacity are associated with differences in the population-level mortality impact of vaccination strategies.

objectivesThis study tested an integrated cross-national structural model examining the interplay between COVID-19 vaccination strategies and country-level macro-structural indicators -the Human Development Index (HDI) and the Containment and Health Index (CHI)- and assessed whether these factors shape vaccination and booster uptake and subsequent COVID-19 mortality change across countries.

methodsUsing country-level data from 195 countries between March 11, 2020, and August 1, 2022, structural path modeling evaluated hypothesized directional pathways among HDI, CHI, vaccination and booster coverage, and COVID-19 mortality change. Variables were standardized and annualized, and before/after ratios captured mortality changes associated with vaccination rollout. Vaccination and booster coverage were measured at a harmonized late-2021 reference point to ensure cross-national comparability prior to outcome assessment.

resultsThe model demonstrated acceptable fit and statistically significant associations within the modeled pathways (p < 0.05). Higher HDI was associated with greater CHI, higher vaccination and booster coverage, and lower mortality change. Booster uptake showed an additional negative association with mortality change, consistent with an implementation pathway linking structural capacity and mortality outcomes.

conclusionsStructural development and policy context were associated with implementation and mortality dynamics at the population level. The integrated global analytical framework suggests that observed mortality dynamics vary according to structural capacity. These findings provide context for global public health decision-making, emphasizing structural readiness alongside biomedical strategies and highlighting the role of health system capacity and governance in shaping differences in the real-world effectiveness of vaccination programs during large-scale infectious threats. Sustained booster uptake emerged as a key operational pathway linking structural capacity to mortality change across countries.

Indexed as

COVID-19COVID-19 VaccinesVaccinationHumansMortalitySocioeconomic Disparities in HealthSocioeconomic FactorsCOVID-19 VaccinesBoosterContainment and health indexCOVID-19COVID-19 mortalityHuman development indexPath modelingVaccination

Identifiers

PMID42420928
PMCPMC13560196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.